Oxford SimCell
Using live bacteria as vaccines and therapies for diseases like cancer has long been seen as an attractive idea, offering a way to target the immune system more comprehensively. Unfortunately the approach is difficult to control, with potentially fatal consequences. SimCell technology solves this problem by producing live bacterial cells that lack genetic material (DNA) and are therefore unable to divide.
Oxford SimCell aims to apply the SimCell technology platform to make genome-sheared, non-dividing bacterial cells as an inactivated whole-cell vaccine against E coli, P aeruginosa and other critical antimicrobial-resistant pathogens. Unlike other inactivation technologies such as heat, irradiation, or chemical inactivation which damage the cells and reduce their ability to induce immune responses, SimCells are unique in offering completely non-replicating bacteria that fully preserve cellular integrity and immunogenicity.
** Currently fundraising **
SimCell on the Move
-
SimCell’s grant application passed European Innovation Council Accelerator’s 1st stage review
-
